Author's response to reviews

Title: Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, ERCC1, and Thymidine Phosphorylase Gene Expression in Primary and Metastatic Gastrointestinal Adenocarcinoma Tissue in Patients Treated on a Phase I Trial of Oxaliplatin and Capecitabine

Authors:

Kazumi Uchida (uchida@hosp.net)
Peter V Danenberg (pdanenbe@usc.edu)
Kathleen D Danenberg (kdanenberg@responsegenetics.com)
Jean L Grem (jgrem@unmc.edu)

Version: 3 Date: 16 November 2008

Author's response to reviews:

Response to BioMed Central Editorial

Re: MS: 1737503351179375 - Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, ERCC1, and Thymidine Phosphorylase Gene Expression in Primary and Metastatic Gastrointestinal Adenocarcinoma Tissue in Patients Treated on a Phase I Trial of Oxaliplatin and Capecitabine

1) Both referees indicate that they are satisfied with the revisions we have made in response to their comments and suggestions.

2) An acknowledgement section is now included that states: “The clinical trial was conducted at the National Naval Medical Center in Bethesda, MD by Dr. Grem when she was employed by the National Cancer Institute, Bethesda, MD. This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. The analyses of the clinical samples performed by Response Genetics, Inc were provided at no charge for this clinical trial.”